Wilting I, Souverein P C, Nolen W A, Egberts A C G, Heerdink E R
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Faculty of Science, Utrecht, the Netherlands.
J Affect Disord. 2008 Nov;111(1):94-9. doi: 10.1016/j.jad.2008.01.019. Epub 2008 Mar 14.
The objectives of the present study were to investigate in outpatients in the Netherlands between 1996 and 2005, changes in 1) the incidence and prevalence of lithium use and 2) lithium use patterns (discontinuation, add-on, and switch).
Incidence and prevalence of lithium use were determined for each year between 1996 and 2005. In addition, we determined cumulative changes in lithium use (discontinuation, add-on, and switching) at three, six, 12 and 24 months for three separate time-cohorts (1998-1999, 2000-2001 and 2002-2003). Lastly, concomitant use of other drugs used in the treatment of bipolar disorders next to lithium during the 24 months after the first lithium prescription was determined for the three time-cohorts.
Incidence of lithium use was constant at approximately 0.2 per 1000 person-years, prevalence increased with 26% from 0.95 to 1.2 per 1000 persons. The percentage of patients receiving an add-on drug used in the treatment of bipolar disorders was constant over the three time-cohorts, with a significant decrease in use of tricyclic antidepressants. Within the patient group that stopped using lithium, more patients switched from lithium to another agent used in the treatment of bipolar disorders over calendar time, and fewer patients discontinued lithium. There was a significant increase in the use of atypical antipsychotics and valproic acid next to lithium.
We did not know the specific diagnosis for which lithium treatment was instituted.
The changes were in line with the increase in alternatives during the last decade and in line with Dutch guidelines.
本研究的目的是调查1996年至2005年期间荷兰门诊患者中,1)锂盐使用的发病率和患病率的变化,以及2)锂盐使用模式(停药、加用和换药)。
确定了1996年至2005年每年锂盐使用的发病率和患病率。此外,我们确定了三个不同时间队列(1998 - 1999年、2000 - 2001年和2002 - 2003年)在3个月、6个月、12个月和24个月时锂盐使用(停药、加用和换药)的累积变化。最后,确定了三个时间队列在首次开具锂盐处方后的24个月内,除锂盐外用于双相情感障碍治疗的其他药物的联合使用情况。
锂盐使用的发病率保持在约每1000人年0.2的恒定水平,患病率从每1000人0.95上升26%至1.2。在三个时间队列中,接受用于双相情感障碍治疗的加用药物的患者百分比保持恒定,三环类抗抑郁药的使用显著减少。在停止使用锂盐的患者组中,随着时间推移,更多患者从锂盐换用另一种用于双相情感障碍治疗的药物,而停用锂盐的患者减少。除锂盐外,非典型抗精神病药物和丙戊酸的使用显著增加。
我们不知道开始锂盐治疗的具体诊断。
这些变化与过去十年中替代药物的增加以及荷兰指南一致。